Glaucoma drug therapy in pregnancy: Literature review and teratology information service (TIS) case series

Marcella Pellegrino, Luisa D’Oria, Carmen De Luca, Giacomina Chiaradia, Angelo Licameli, Caterina Neri, Marta Nucci, Daniela Visconti, Alessandro Caruso, Marco De Santis

Research output: Contribution to journalReview article

Abstract

Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications. Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women. Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes. Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.

Original languageEnglish
Pages (from-to)3-11
Number of pages9
JournalCurrent Drug Safety
Volume13
Issue number1
DOIs
Publication statusPublished - Mar 1 2018

Keywords

  • Congenital anomalies
  • Drugs
  • Glaucoma
  • Pregnancy
  • Prenatal diagnosis
  • Teratology Information Service (TIS)

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Glaucoma drug therapy in pregnancy: Literature review and teratology information service (TIS) case series'. Together they form a unique fingerprint.

  • Cite this

    Pellegrino, M., D’Oria, L., De Luca, C., Chiaradia, G., Licameli, A., Neri, C., Nucci, M., Visconti, D., Caruso, A., & De Santis, M. (2018). Glaucoma drug therapy in pregnancy: Literature review and teratology information service (TIS) case series. Current Drug Safety, 13(1), 3-11. https://doi.org/10.2174/1574886312666171030125804